Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
ZOLMITRIPTAN
VANC PHARMACEUTICALS INC
N02CC03
ZOLMITRIPTAN
2.5MG
TABLET
ZOLMITRIPTAN 2.5MG
ORAL
100
Prescription
SELECTIVE SEROTONIN AGONISTS
Active ingredient group (AIG) number: 0134381001; AHFS:
CANCELLED PRE MARKET
2019-07-31
Page | 1 PRODUCT MONOGRAPH PR VAN-ZOLMITRIPTAN ZOLMITRIPTAN TABLETS 2.5 MG 5-HT 1 Receptor Agonist MIGRAINE THERAPY MANUFACTURER AND DISTRIBUTOR: Vanc Pharmaceuticals Inc. Date of Preparation: March 25, 2015 Unit-210, 2639 Viking Way Richmond, BC V6V 3B7 www.vancpharm.com Control# 182335 Page | 2 TABLE OF CONTENTS PRODUCT MONOGRAPH ...................................................................................................... 1 TABLE OF CONTENTS .......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS ..................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................... 5 ADVERSE REACTIONS .................................................................................................... 11 DRUG INTERACTIONS .................................................................................................... 17 DOSAGE AND ADMINISTRATION ................................................................................ 19 OVERDOSAGE .................................................................................................................. 20 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 20 STORAGE AND STABILITY ............................................................................................ 23 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 23 PART II: SCIENTIFIC INFORMATION ............................................................................... 24 PHARMACEUTICAL INFORMATIO Կարդացեք ամբողջական փաստաթուղթը